
Annual report 2024
added 12-27-2025
Medigus Ltd. Revenue 2011-2025 | MDGS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Medigus Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.9 M | 91.7 M | 91.9 M | 10.1 M | 531 K | 273 K | 436 K | 467 K | 549 K | 619 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 91.9 M | 273 K | 22.6 M |
Quarterly Revenue Medigus Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54 K | - | - | - | 82 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 82 K | 54 K | 68 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.47 | -3.61 % | $ 120 M | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 96.06 | -0.04 % | $ 141 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.35 | -1.99 % | $ 671 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 303.76 | 0.52 % | $ 8.57 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 47.89 | -0.48 % | $ 7.14 K | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Abbott Laboratories
ABT
|
42 B | $ 124.72 | -0.1 % | $ 217 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.3 | 11.09 % | $ 123 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.62 | 1.04 % | $ 1.16 B | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.21 | 6.14 % | $ 19.5 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
LivaNova PLC
LIVN
|
1.25 B | $ 62.92 | -0.25 % | $ 3.41 B | ||
|
Align Technology
ALGN
|
4 B | $ 158.62 | 0.49 % | $ 11.9 B | ||
|
NanoVibronix
NAOV
|
2.56 M | - | - | $ 1.08 M | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.83 | -3.49 % | $ 85.3 M | ||
|
LENSAR
LNSR
|
53.5 M | $ 12.03 | 0.17 % | $ 139 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 97.53 | 0.48 % | $ 1.24 B | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 14.04 | -3.13 % | $ 379 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 14.51 | -0.13 % | $ 95.1 M | ||
|
AxoGen
AXGN
|
187 M | $ 32.87 | 0.7 % | $ 1.45 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 40.89 | 2.12 % | $ 1.26 B | ||
|
OrthoPediatrics Corp.
KIDS
|
205 M | $ 17.36 | -0.29 % | $ 401 M | ||
|
Globus Medical
GMED
|
2.52 B | $ 88.38 | -0.15 % | $ 12 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 12.65 | -0.08 % | $ 974 M | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Aethlon Medical
AEMD
|
574 K | $ 2.58 | 3.61 % | $ 4.03 M | ||
|
Myomo
MYO
|
1 B | $ 1.02 | - | $ 7.19 M |